DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 04/25/2019 -- Merkel Cell Carcinoma - Epidemiology and Market Forecast-2028

Approximately 60% of Merkel Cell Carcinoma tumours arise in men.

1. Approximately 2500 persons per year are diagnosed with this cancer in the United States.
2. The incidence has tripled in the United States, and it can be lethal for about one-third of the people affected.
3. The incidence is approximately 0.7 people per 100,000 people in the general population of the United States.

DelveInsight launched a new report on Merkel Cell Carcinoma - Market Insights, Epidemiology and Market Forecast-2028

Request for sample pages

Key benefits

1. Merkel Cell Carcinoma market report covers a descriptive overview and comprehensive insight of the Merkel Cell Carcinoma epidemiology and Merkel Cell Carcinoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Merkel Cell Carcinoma market report provides insights into the current and emerging therapies.
3. Merkel Cell Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Merkel Cell Carcinoma market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Merkel Cell Carcinoma market.

"There is a 100,000-fold difference between the risks of developing Merkel Cell Carcinoma for patients under the age of 30 compared to those who are greater than 85 years old."

Merkel Cell Carcinoma treatment is based mainly on the stage of the disease and the overall health of the patient, as there are currently no approved therapies for advanced-stage Merkel Cell Carcinoma.

Merkel Cell Carcinoma treatments along with surgical excision, are radiation and chemotherapy, but some revolutionary therapies have recently moved into the forefront. Significant progress has been made in the understanding of Merkel Cell Carcinoma tumor biology and immunology. Recent advances in the development of well-tolerated immunotherapy agents have the potential to provide effective treatment options for patients with advanced or recurrent Merkel Cell Carcinoma in the future. Immunotherapy with the PD1–PDL1 immune-checkpoint pathway is a key therapeutic target in reactivating immune responses against various types of cancers.

The launch of the emerging therapies is expected to significantly impact the Merkel Cell Carcinoma treatment scenario in the upcoming years, 2017-2028.

The key players in Carcinoid Tumors market are:
1. Bristol-Myers Squibb
2. NantKwest
3. Kartos Therapeutics
4. Incyte Corporation
and many others

Drugs covered
1. INCMGA00012
2. Nivolumab
3. KRT 232
4. haNk and aNK cell therapies
And many others

Table of contents

1. Report Introduction
2. Merkel Cell Carcinoma Market Overview at a Glance
3. Merkel Cell Carcinoma Disease Background and Overview
4. Merkel Cell Carcinoma Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Merkel Cell Carcinoma 7MM Incident cases (2017-2028)
4.3. Merkel Cell Carcinoma Gender-Specific cases (2017-2028)
4.4. Merkel Cell Carcinoma Stage-Specific cases (2017-2028)
4.5. Merkel Cell Carcinoma Diagnosed and Treatable cases (2017-2028)
4.6. Merkel Cell Carcinoma Country- Wise Epidemiology
4.7. United States
4.8. EU-5
4.9. Assumptions and Rationale
4.10. Germany
4.11. France
4.12. Italy
4.13. Spain
4.14. United Kingdom
4.15. Japan
5. Merkel Cell Carcinoma Treatments & Medical Practices
6. Merkel Cell Carcinoma Marketed Therapies
6.1. Pembrolizumab: Merck
6.2. Avelumab: Merck
7. Emerging Therapies
8. Key Cross Competition
8.1. INCMGA00012:Incyte corporation
8.2. haNK cell therapy: NantKwest
8.3. aNK cell therapy: NantKwest
9. Merkel Cell Carcinoma Market Size
10. 7MM Merkel Cell Carcinoma Country-Wise Market Analysis
11. United States Market Size
12. Germany Market Size
13. France Market Size
14. United Kingdom Market Size
15. Spain Market Size
16. Italy Market Size
17. Japan Market Size
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

New Delhi, India -- (SBWIRE) -- 04/09/2018 -- Critical Limb Ischemia (CLI) is a severe form of peripheral artery disease (PAD). It occurs with severe obstructions in the arteries which leads to reduced blood flow to the extremities. CLI causative occlusion could be acute or chronic. CLI may progress to severe pain and skin ulcers and is associated with high risk cardiovascular events such as myocardial infarction and mortality. CLI can also be divided into rest pain and tissue loss based on symptoms appears. Rest pain is a continuous burning pain of the lower leg whereas tissue loss is the development of gangrene or arterial insufficiency ulcers.

According to the latest report of DelveInsight, "Critical Limb Ischemia (CLI)- Market Insights, Epidemiology and Market Forecast- 2027", Around 300 per million cases of CLI arises each year in the United States. The estimated prevalence in Japan is 1 per million population whereas 4.2 per million Western European are suffering from this condition. CLI is associated with severe morbidity and mortality. On first year, 25% of patients will be dead, 30% may undergo amputation, and only 45% will remain alive with both limbs. At 5 years, more than 60% of patients with critical limb ischemia will be dead. More than 20% of adults age 70 and older are diagnosed with CLI. The prevalence of critical limb ischemia is slightly more in men than women

There is no drug approved for the treatment of Critical Limb Ischemia however, the current treatment practices are based on the symptoms and complexity of the conditions. Endovascular treatment and arterial surgery are other approaches to remove the blockage. Many players such as Pluristem Ltd., Rexgenero Ltd., Juventas Therapeutics, Inc., Caladrius Biosciences Inc., Reven Pharmaceuticals, Inc., and others are involved in developing therapies for Critical Limb Ischemia. The launch of potential emerging therapies such as PLX-PAD (Pluristem Ltd.), Rexmyelocel-T (Rexgenero Limited), JVS-100 (Juventas Therapeutics, Inc.) and CLBS12 (Caladrius Biosciences, Inc.) are expected to change the treatment landscape in upcoming years.

The latest report has covered detailed description about current treatment and medical practices. Complete Pipeline drugs profiling covering each and every phase of development with clinical trials data. Total market size of CLI is provided covering the 7MM with country-wise market analysis to better understand the areas of improvement and growth opportunities in the market. Complete Epidemiology and patient population details are provided covering the 7MM to better understand the distribution of the given indication in 7MM. Key emerging therapy details are also provided to better understand the future market competition and plan the strategies accordingly.

Reasons to buy:
-The report will help in developing business strategies by understanding trends shaping and driving the CLI market.
-To understand the future market competition in the CLI market and Insight reviews of the key market drivers and barriers.
-Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
-In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:
-Caladrius Biosciences,
-Juventas Therapeutics,
-Rexgenero Limited
-Pluristem Ltd.
And many others……………..

Request for sample pages: https://www.delveinsight.com/report-store/critical-limb-ischemia-market-insight-epidemiology-and-market-forecast

related sample pages: https://www.delveinsight.com/report-store/critical-limb-ischemia-pipeline-insight

Table of Contents:
1. Report Introduction
2. Critical Limb Ischemia Market Overview at a Glance
2.1. Global Market Size of Critical Limb Ischemia in 2017
2.2. Global Market Size of Critical Limb Ischemia in 2027
3. Disease Background and Overview: Critical Limb Ischemia
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Critical Limb Ischemia Geography wise Prevalent Cases
4.2.1. 7MM Prevalent Cases of Critical Limb Ischemia (2017-2027)
4.2.2. Age Specific Prevalent Cases of Critical Limb Ischemia (2017-2027)
4.3. United States
4.3.1. Prevalent Cases of Critical Limb Ischemia in the US (2016-2027)
4.3.2. Age Specific Prevalent Cases of Critical Limb Ischemia in the US (2016-2027)
4.3.3. Diagnosed and Treatable population of Critical Limb Ischemia in the US (2016-2027)
4.4. EU-5
4.4.1. Assumptions and Rationale
4.4.2. Germany
4.4.2.1. Prevalent Cases of Critical Limb Ischemia in Germany (2016-2027)
4.4.2.2. Age Specific Prevalent Cases of Critical Limb Ischemia in Germany (2016-2027)
4.4.2.3. Diagnosed and Treatable population of Critical Limb Ischemia in Germany (2016-2027)
4.4.3. Italy
4.4.3.1. Prevalent Cases of Critical Limb Ischemia in Italy (2016-2027)
4.4.3.2. Age Specific Prevalent Cases of Critical Limb Ischemia in Italy (2016-2027)
4.4.3.3. Diagnosed and Treatable population of Critical Limb Ischemia in Italy (2016-2027)
4.4.4. Spain
4.4.4.1. Prevalent Cases of Critical Limb Ischemia in Spain (2016-2027)
4.4.4.2. Age Specific Prevalent Cases of Critical Limb Ischemia in Spain (2016-2027)
4.4.4.3. Diagnosed and Treatable population of Critical Limb Ischemia in Spain (2016-2027)
4.4.5. France
4.4.5.1. Prevalent Cases of Critical Limb Ischemia in France (2016-2027)
4.4.5.2. Age Specific Prevalent Cases of Critical Limb Ischemia in France (2016-2027)
4.4.5.3. Diagnosed and Treatable population of Critical Limb Ischemia in France (2016-2027)
4.4.6. United Kingdom
4.4.6.1. Prevalent Cases of Critical Limb Ischemia in the UK (2016-2027)
4.4.6.2. Age Specific Prevalent Cases of Critical Limb Ischemia in the UK (2016-2027)
4.4.6.3. Diagnosed and Treatable population of Critical Limb Ischemia in the UK (2016-2027)
4.5. Japan
4.5.1. Prevalent Cases of Critical Limb Ischemia in Japan (2016-2027)
4.5.2. Age Specific Prevalent Cases of Critical Limb Ischemia in Japan (2016-2027)
4.5.3. Diagnosed and Treatable population of Critical Limb Ischemia in Japan (2016-2027)
5. Current Treatment and Medical Practices
5.1. United States
5.2. Europe
5.3. Japan
6. Key Emerging Therapies
6.1. Key Cross Competition
6.2. PLX-PAD: Pluristem Ltd.
6.2.1. Regulatory Milestones
6.2.2. Clinical Development
6.2.3. Product Profile
6.2.4. Clinical Pipeline Activity
6.2.4.1. Ongoing Trials Information
6.2.4.2. Clinical Trial by Phase
6.3. Rexmyelocel-T: Rexgenero Limited
6.3.1. Regulatory Milestones
6.3.2. Clinical Development
6.3.3. Product Profile
6.3.4. Clinical Pipeline Activity
6.3.4.1. Ongoing Trials Information
6.3.4.2. Clinical Trial by Phase
6.4. JVS-100: Juventas Therapeutics, Inc.
6.4.1. Regulatory Milestones
6.4.2. Clinical Development
6.4.3. Product Profile
6.4.4. Clinical Pipeline Activity
6.4.4.1. Ongoing Trials Information
6.4.4.2. Clinical Trial by Phase
6.5. CLBS12: Caladrius Biosciences, Inc.
6.5.1. Regulatory Milestones
6.5.2. Clinical Development
6.5.3. Product Profile
6.5.4. Clinical Pipeline Activity
6.5.4.1. Ongoing Trials Information
6.5.4.2. Clinical Trial by Phase
To be continued in report…
7. Critical Limb Ischemia Market Size
7.1. Key Findings
7.2. Total 7MM Critical Limb Ischemia Market Analysis
7.2.1. Overview of Total Critical Limb Ischemia Market (2016-2027)
8. 7MM Critical Limb Ischemia: Country-Wise Market Analysis
8.1. United States Market Size
8.1.1. Market Analysis
8.1.2. Emerging therapies analysis: Impact on the market
8.2. Germany Market Size
8.2.1. Market Analysis
8.2.2. Emerging therapies analysis: Impact on the market
8.3. France Market Size
8.3.1. Market Analysis
8.3.2. Emerging therapies analysis: Impact on the market
8.4. United Kingdom Market Size
8.4.1. Market Analysis
8.4.2. Emerging therapies analysis: Impact on the market
8.5. Spain Market Size
8.5.1. Market Analysis
8.5.2. Emerging therapies analysis: Impact on the market
8.6. Italy Market Size
8.6.1. Market Analysis
8.6.2. Emerging therapies analysis: Impact on the market
8.7. Japan Market Size
8.7.1. Market Analysis
8.7.2. Emerging therapies analysis: Impact on the market
9. Report Methodology
9.1. Sources Used
10. Delveinsight Capabilities
11. Disclaimer

About Delveinsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses.

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight‘s report, “PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2017” gives the comprehensive insights on the PD-1 and PD-L1 Inhibitors.

New Delhi, India -- (SBWIRE) -- 05/19/2017 -- "PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2017" report provides the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors including information of Marketed molecules, detailed profiling of Pipeline assets and their pathways. The report covers the therapeutics assessment of pipeline molecules by the mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. The report deals with the detailed epidemiology of all prevalent indications.

Report also covers other Commercial Aspects such as the Current and Future Market, Barriers and challenges, SWOT analysis. Report describes the possible unmet needs covered by PD-1 and PD-L1 inhibitors, highlighting the side effects and toxic effects related to PD-1 and PD-L1 inhibitors which are major concerns in the market for the usage of PD-1 and PD-L1 inhibitors.

The report throws light on the combinations therapies with Immune-check point Inhibitors (PD-1 and PD-L1) and provides information on ongoing collaborations for the development of combinations regimens.

Major active therapy areas include Metastatic Renal Cell Carcinoma, Squamous Cell Carcinomas of the Head and Neck, Metastatic Colorectal Cancer and Non-Small Cell lung cancer.

DelveInsight Analysis predicts that PD-1 and PD-L1 inhibitors are among the highly growing fields in the bio-pharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. There are 50+ active drugs in the pipeline. Companies have also gone in collaboration with different partners like for evaluating their drugs in combination with Immune Checkpoint Inhibitors (PD-1/PD-L1). There are approximately 40 companies which are active in the development of different drugs targeting PD-1 and PD-L1.

The future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. There are 3 marketed products of PD-1 and PD-L1 inhibitors. Treatment options such as surgery, chemotherapy, radiation therapy, and many others are able to fulfill the current unmet need to an extent. With 7 drugs in the Phase III pipeline of the PD-1 and PD-L1 inhibitors, the market looks promising in coming years as well.

About DelveInsight
DelveInsight is a Business Consultant company and serves as a Knowledge partner across the value chain of Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios, and companies.

Contact Information:

DelveInsight Business Research

Contact number: +91-11-4568 9769

email: info@delveinsight.com

https://www.delveinsight.com/

Follow us on:

Twitter; Linkedin

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm